mdlinx mdlinx

Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with Type 2 diabetes uncontrolled by oral agents Journal of Diabetes and its Complications, 05/17/2012

Sakharova OV et al. - In type 2 diabetes patients failing oral anti-hyperglycemic drugs (OADs) therapy, an initial insulin regimen of twice daily premixed insulin results in significantly improved post-prandial glucose levels as well as a reduction in a precursor of AGEs. The effect of these two initial insulin regimens on long-term diabetic complications requires further study.

Methods
  • This was a 6-month, open-label, single-center study using a cross-over design.
  • 14 subjects were randomized to one of two protocols: once daily insulin glargine or twice-daily 75%/25% neutral protamine lispro/lispro mix.
  • At 12 weeks, the subjects were crossed-over to the opposite protocol.
  • During each period, insulin doses were titrated to target fasting blood glucose of 90–110mg/dL.
  • At baseline and after the two 12-week treatment periods, subjects were studied in the Clinical Research Center; they consumed three liquid mixed isocaloric meals at 4-h intervals, and glucose, free fatty acids (FFA), lipids, and α-dicarbonyls (3-deoxyglucosone [3-DG] and methylglyoxal [MG]) were measured before and after each meal.
  • Patient data were analyzed in the context of their assigned insulin strategy groups.

Results
  • Both insulin regimens led to a significant improvement in glycemic profiles, including fasting glucose and HbA1c, compared to baseline.
  • However, mean post-prandial glucose was lower with lispro mix than with glargine (153±36 vs. 199±49 mg/dL, respectively; P=0.001).
  • Likewise, there was a reduction in both fasting (48±13 vs. 57±19, P=0.047) and post-prandial (53±19 vs. 63±23; P=0.007) 3DG levels with lispro mix as compared to glargine.
  • No differences were noted in MG concentrations.

Read this article on Journal of Diabetes and its Complications



Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close